Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Oct 31, 2025 | (Q1)Jul 31, 2025 | (FY)Apr 30, 2025 | (Q4)Apr 30, 2025 | (Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (FY)Apr 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 69.88K | 19.5K | 65.29K | 65.29K | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --69.88K | --19.5K | --65.29K | --65.29K | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | |||||||||
| Gross profit | |||||||||
| Operating expense | 1,931.65%3.68M | 1,550.46%2.67M | 1,692.44%4.76M | 1.99M | 2.43M | 181.1K | 161.82K | 113,414.96%265.63K | 234 |
| Selling and administrative expenses | 1,982.56%2.78M | 342.29%547.1K | 989.18%2.89M | --1.28M | --1.4M | --133.48K | --123.7K | 113,414.96%265.63K | --234 |
| -Selling and marketing expense | ---- | ---- | ---- | ---- | ---- | --17.1K | --13.13K | ---- | ---- |
| -General and administrative expense | 1,982.56%2.78M | 342.29%547.1K | 989.18%2.89M | --1.28M | --1.4M | --133.48K | --123.7K | 113,414.96%265.63K | --234 |
| Research and development costs | 1,426.59%458.71K | 989.70%272.42K | --242.3K | --30.21K | --115.63K | --30.05K | --25K | ---- | ---- |
| Other operating expenses | 2,408.59%440.76K | 14,005.05%1.85M | --1.63M | --678.28K | --916.75K | --17.57K | --13.13K | ---- | ---- |
| Operating profit | -1,893.06%-3.61M | -1,538.41%-2.65M | -1,667.86%-4.7M | -1.93M | -2.43M | -181.1K | -161.82K | -113,414.96%-265.63K | -234 |
| Net non-operating interest income (expenses) | |||||||||
| Other net income (expenses) | -309.21%-1.91K | 99.75%-387 | -2,350.33%-3.8M | -3.66M | 19.54K | -467 | -155.03K | -155.03K | |
| Gain on sale of security | ---1.91K | ---387 | ---9.74K | ---4.39K | ---5.35K | ---- | ---- | ---- | ---- |
| Special income (charges) | --0 | --0 | -2,360.12%-3.81M | ---3.68M | --24.89K | --0 | ---155.03K | ---155.03K | ---- |
| -Less:Restructuring and mergern&acquisition | --0 | --0 | 0.00%155.03K | --24.89K | ---24.89K | --0 | --155.03K | --155.03K | ---- |
| -Less:Impairment of capital assets | ---- | ---- | --3.66M | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | ---- | ---- | --24.91K | ---- | ---- | ---- | ---- | ---- | ---- |
| Income before tax | -1,894.12%-3.61M | -736.89%-2.65M | -1,919.38%-8.49M | -5.59M | -2.41M | -181.1K | -316.85K | -179,666.67%-420.65K | -234 |
| Income tax | |||||||||
| Earnings from equity interest net of tax | |||||||||
| Net income | -1,894.12%-3.61M | -736.89%-2.65M | -1,919.38%-8.49M | -5.59M | -2.41M | -181.1K | -316.85K | -179,666.67%-420.65K | -234 |
| Net income continuous operations | -1,894.12%-3.61M | -736.89%-2.65M | -1,919.38%-8.49M | ---5.59M | ---2.41M | ---181.1K | ---316.85K | -179,666.67%-420.65K | ---234 |
| Noncontrolling interests | |||||||||
| Net income attributable to the company | -1,894.12%-3.61M | -736.89%-2.65M | -1,919.38%-8.49M | -5.59M | -2.41M | -181.1K | -316.85K | -179,666.67%-420.65K | -234 |
| Preferred stock dividends | |||||||||
| Other under preferred stock dividend | |||||||||
| Net income attributable to common stockholders | -1,894.12%-3.61M | -736.89%-2.65M | -1,919.38%-8.49M | -5.59M | -2.41M | -181.1K | -316.85K | -179,666.67%-420.65K | -234 |
| Diluted earnings per share | -1,587.97%-0.07 | -507.16%-0.05 | -2,300.00%-0.24 | -0.16 | -0.06 | -0.0041 | -0.0082 | -166,566.67%-0.01 | -0 |
| Basic earnings per share | -1,587.97%-0.07 | -507.16%-0.05 | -2,300.00%-0.24 | -0.16 | -0.06 | -0.0041 | -0.0082 | -166,566.67%-0.01 | -0 |
| Dividend per share | |||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.